AR Signaling and the PI3K Pathway in Prostate Cancer.
AR Signaling and the PI3K Pathway in Prostate Cancer.
复制标题
DOI：
10.3390/cancers9040034
复制
发表时间：
2017-04-15
期刊：
影响因子：
5.2
通讯作者：
Joshua AM
中科院分区：
文献类型：
--
作者：
Crumbaker M;Khoja L;Joshua AM
前列腺癌是全球男性癌症相关死亡的主要原因。雄激素途径中的异常信号在前列腺癌的发生和发展中起关键作用。尽管在去势耐受疾病中持续依赖雄激素受体(AR)信号，但除了开发有效的雄激素靶向药物外，患者总是会产生治疗耐药。AR和PI3K通路之间的相互作用可能是耐药的一种机制，该通路的抑制剂已被开发出来并取得了不同的成功。在此，我们概述了PI3K通路在前列腺癌中的作用，特别是它与雄激素受体信号在前列腺癌发生和发展中的关系，以及PI3K靶向的临床应用。
Prostate cancer is a leading cause of cancer-related death in men worldwide. Aberrant signaling in the androgen pathway is critical in the development and progression of prostate cancer. Despite ongoing reliance on androgen receptor (AR) signaling in castrate resistant disease, in addition to the development of potent androgen targeting drugs, patients invariably develop treatment resistance. Interactions between the AR and PI3K pathways may be a mechanism of treatment resistance and inhibitors of this pathway have been developed with variable success. Herein we outline the role of the PI3K pathway in prostate cancer and, in particular, its association with androgen receptor signaling in the pathogenesis and evolution of prostate cancer, as well as a review of the clinical utility of PI3K targeting.